Gene Editing in Cancer Therapy

Article Sidebar

PDF
Published: Oct 25, 2022
DOI: https://doi.org/10.47191/ijmscrs/v2-i10-22
Keywords:
.

Main Article Content

Gloria Nataly Pérez Serrano
Universidad Autónoma de Guadalajara
Alejandra Jeraldine Gonzalez Barajas
Universidad Autónoma de Guadalajara

Abstract

The site-specific modification of an existing gene is known as gene editing. A section of DNA must be cut with an endonuclease (such as the CRISPR-Cas9 system) before the two severed ends are brought together, frequently with a new or improved sequence inserted between them. Somatic cell gene editing can be helpful in a variety of clinical contexts, and some preliminary preclinical and clinical trials have been carried out. Extremely high levels of precision are required for DNA recognition, excision, and repair; issues with publishing integrity must be resolved. Germline editing utilizing eggs, sperm, or embryos raises ethical concerns.

Article Details

How to Cite
Serrano, Gloria Nataly Pérez, and Alejandra Jeraldine Gonzalez Barajas. 2022. “Gene Editing in Cancer Therapy”. International Journal of Medical Science and Clinical Research Studies 2 (10):1120-22. https://doi.org/10.47191/ijmscrs/v2-i10-22.
Issue
Vol. 2 No. 10 (2022): Volume 02 Issue 10 October 2022
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Mao, Y., Botella, J. R., Liu, Y., & Zhu, J. K. (2019). Gene editing in plants: progress and challenges. National Science Review, 6(3), 421-437.

II. Mosbach, V., Poggi, L., & Richard, G. F. (2019). Trinucleotide repeat instability during double-strand break repair: from mechanisms to gene therapy. Current genetics, 65(1), 17-28.

III. Salsman, J., & Dellaire, G. (2017). Precision genome editing in the CRISPR era. Biochemistry and cell biology, 95(2), 187-201.

IV. Singh, V., Braddick, D., & Dhar, P. K. (2017). Exploring the potential of genome editing CRISPR-Cas9 technology. Gene, 599, 1-18.

V. Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020). Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. Nature biotechnology, 38(7), 824-844.

VI. Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010). Genome editing with engineered zinc finger nucleases. Nature Reviews Genetics, 11(9), 636-646.

VII. Sun, N., & Zhao, H. (2013). Transcription activator‐like effector nucleases (TALENs): a highly efficient and versatile tool for genome editing. Biotechnology and bioengineering, 110(7), 1811-1821.

VIII. Moreno-Mateos, M. A., Fernandez, J. P., Rouet, R., Vejnar, C. E., Lane, M. A., Mis, E., ... & Giraldez, A. J. (2017). CRISPR-Cpf1 mediates efficient homology-directed repair and temperature-controlled genome editing. Nature communications, 8(1), 1-9.

IX. Prado, G. S., Pinheiro, T. T., de FARIA, J. C., & VIANELLO, R. (2021). Genome editing via non-homologous end-joining (NHEJ) and ribonucleoproteins (RNP).

X. Holt, N., Wang, J., Kim, K., Friedman, G., Wang, X., Taupin, V., ... & Cannon, P. M. (2010). Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nature biotechnology, 28(8), 839-847.

XI. Li, Y., Glass, Z., Huang, M., Chen, Z. Y., & Xu, Q. (2020). Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications. Biomaterials, 234, 119711.

XII. Lee, B. C., Lozano, R. J., & Dunbar, C. E. (2021). Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells. Molecular Therapy, 29(11), 3205-3218.

XIII. Rossant, J. (2018). Gene editing in human development: ethical concerns and practical applications. Development, 145(16), dev150888.

Most read articles by the same author(s)